CMS Medicaid Outcomes 
DAIC
MARCH 13, 2024
CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage.
DAIC
JANUARY 30, 2025
By integrating a real-time frailty risk score into the electronic medical record (EMR), presenting stroke severity and other variables, we can proactively identify who will benefit from immediate surgery and who may need pre-habilitating before surgery to achieve better outcomes.
DAIC
MAY 2, 2024
The CardiAMP cell therapy trials for the indications of both chronic myocardial ischemia and ischemic heart failure are covered by the Center for Medicare and Medicaid for both treatment and control procedures. CAUTION - Limited by United States law to investigational use.
DAIC
MARCH 7, 2024
Despite improvements with current medications and devices, heart failure remains at epidemic proportions and we now have an exciting opportunity for a therapy to improve important, objective outcomes, such as mortality and hospital re-admissions rates. “We The CardiAMP HF II trial is expected to similarly secure CMS reimbursement.
DAIC
JULY 25, 2024
The CardiAMP clinical development for heart failure is supported by the Maryland Stem Cell Research Fund and is reimbursed by Center for Medicare and Medicaid Services (CMS) for both treatment and control procedures. CAUTION - Limited by United States law to investigational use.
DAIC
JUNE 4, 2024
To improve outcomes and be in compliance with new regulations, it's crucial to better identify and address these issues during the recovery period. Stroke recovery is a challenging process that extends for months after hospital discharge. This missing puzzle piece matters now more than ever.
CardiacWire
MARCH 24, 2024
Less than two weeks after Novo Nordisk’s weight-loss drug Wegovy gained expanded FDA approval for cardiovascular event risk reduction, CMS issued a new Medicare Part D guidance that allows coverage of obesity drugs for senior patients with “an additional medically accepted indication”… like cardiovascular disease.
Expert insights. Personalized for you.
111 
Let's personalize your content